ISRCTN16928142已完成1 期
Bioavailability and proof of concept study of a new modified release losartan formulation versus the marketed formulation Cozaar® administered to healthy volunteers under fasting conditions
DPL Pharma S.p.A.0 个研究点目标入组 16 人开始时间: 2022年4月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Informed consent: signed written informed consent before inclusion in the study
- •2. Men, 18-55 years old inclusive
- •3. Body Mass Index: 18.5-30 kg/m² inclusive
- •4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
- •5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study
排除标准
- •1. Electrocardiogram (ECG, 12-leads, supine position): clinically significant abnormalities
- •2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
- •3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- •4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- •5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study. Known renal dysfunction
- •6. Medications: medications, including over the counter medications and herbal products for 2 weeks before the start of the study
- •7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
- •8. Blood donation: blood donations for 3 months before this study
- •9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (>2 drinks/day, defined according to the USDA Dietary Guidelines 2015-2020), caffeine (>5 cups coffee/tea/day) or tobacco abuse (=10 cigarettes/day)
- •10. Drug test: positive result at the drug test at screening or day -1 (all study periods)
- •11. Alcohol test: positive alcohol breath test at day -1 (all study periods)
- •12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
研究者
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and bioavailability of ibuprofen lysinatePain on an inflammatory basis (otitis and otomastoiditis, adenite, cellulite, arthritis) and post-operative painMedDRA version: 21.0Level: PTClassification code 10050533Term: Pain assessmentSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: LLTClassification code 10063374Term: Pain scaleSystem Organ Class: 10022891 - InvestigationsEUCTR2019-000647-27-ITDicofarm S.p.A.84
进行中（未招募）
不适用
A study to compare a pediatric tablet or suspension of elvitegravir verses the adult 150 mg tablet in healthy adult volunteersHuman Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2015-000725-37-Outside-EU/EEAGilead Sciences, Inc.78
已完成
不适用
Proof of concept study to investigate bioavailability of two different Curcumin formulations in healthy subjects: a randomized, controlled, cross-over studyHealthy subjectsDRKS00026962nternehmen zur Herstellung und Vertrieb von Nahrungsergänzungsmitteln6
已完成
1 期
A Phase 1 Study of Two PRN1008 Tablet Formulations and the impact of Midazolam and Famotidine on PRN1008 in Healthy SubjectsACTRN12618000249257Principia Biopharma Inc14
进行中（未招募）
1 期
Phase I Relative Bioavailability and food effect studyEUCTR2016-002895-29-DEBayer AG